Arizona Bioscience News: UA develops blood test to detect cancer; Flagstaff honors STEM leaders; SARRC to expand statewide

May 30, 2019

By Matt Ellsworth

UA researchers look to bring new blood tests for cancer to market / Arizona Daily Star 
 
Researchers at the University of Arizona have developed a new blood test that can detect most major cancers, and have launched the startup company, DesertDx, with the help of Tech Launch Arizona to bring the technology to doctors and patients. Read more: UA develops blood test for cancer 


Autism research center to expand throughout Arizona by 2030 / KTAR 
 
The Southwest Autism Research and Resource Center intends to expand its programs beyond Maricopa County to the entire state by 2030, including at least 10 resource centers. Read more: Early autism screening proves to be a success for children with developmental delays 


STEMMYs recognize STEM leaders, new STEM City director / Arizona Daily Sun 

Flagstaff’s science, technology, engineering and mathematics enthusiasts young and old were recognized at STEM City’s seventh annual STEM Awards, where past and current advocates and the future of STEM were celebrated.


Stem cell study reveals most toxic vape flavors / AZ Big Media 

Researchers at the University of Arizona College of Medicine-Phoenix and others, using stem cells to investigate the impact of e-liquids on cardiovascular disease, have revealed the harmful effects of flavored e-cigarette liquids and e-cigarette use. 


Banner Health launches Banner Innovation Group / AZ Big Media 

Banner Health launched the Banner Innovation Group in May, an initiative created to merge two groups at Banner to develop and implement programs that enhance and improve patients’ health care experience, including working with entrepreneurs and partners to commercialize ideas. 


In the war against brain cancer, accelerated clinical trials are a crucial strategy / Town of Paradise Valley Independent (Op-ed) 

Dr. Nader Sanai, Francis & Dionne Najafi Professor of Neurosurgical Oncology at the Barrow Neurological Institute in Phoenix, writes about accelerated clinical trials for brain tumors that test new, experimental drug combinations on a patient-by-patient basis.  


Sign up to receive Arizona Bioscience News weekly